167 results
Page 5 of 9
424B5
wkltk
10 Feb 21
Prospectus supplement for primary offering
4:53pm
424B5
frtptd 75465vx
9 Feb 21
Prospectus supplement for primary offering
5:24pm
6-K
EX-99.1
khnxrof5813ncu6
17 Dec 20
Mereo BioPharma and Ultragenyx Announce Collaboration and License
5:16pm
6-K
EX-99.1
wawm9 9r16h
15 Dec 20
Current report (foreign)
2:22pm
6-K
EX-99.1
gmw4fprfvcn k4ncaad
16 Nov 20
Current report (foreign)
7:27am
6-K
EX-99.1
b9ib2xkg2fc6ratbwab0
12 Nov 20
Current report (foreign)
6:15am
424B5
qhuvo7yf
23 Oct 20
Prospectus supplement for primary offering
4:40pm
6-K
EX-99.1
bsrc86ubwownh
20 Oct 20
Mereo BioPharma Appoints Christine Fox as Chief Financial Officer and Heidi Petersen as Senior Vice President, Regulatory Affairs
7:12am
6-K
EX-99.1
ycevmvqn9t
19 Oct 20
Current report (foreign)
8:10am
6-K
EX-99.1
ysbpnjooxz6z3wn
7 Oct 20
Mereo BioPharma Files Registration Statement on Form F-3 with U.S. Securities and Exchange Commission
9:53am
F-3
dyelg
6 Oct 20
Shelf registration (foreign)
4:25pm
F-3
EX-1.2
mutgert
6 Oct 20
Shelf registration (foreign)
4:25pm
F-6EF
EX-99
f6ntm9ysu4
6 Oct 20
Automatic registration for ADRs (foreign)
4:10pm
6-K
EX-99.2
o3odau4my6 cjryq
29 Sep 20
Current report (foreign)
7:08am
6-K
EX-99.1
t02em6m uchf
29 Sep 20
Current report (foreign)
7:08am
6-K
EX-99.1
bbhwmr2txbv2qpuo
28 Sep 20
Mereo BioPharma Announces Changes to Board of Directors
8:08am
6-K
EX-99.1
7446yrupluk2v76 2kd
24 Sep 20
Mereo BioPharma Receives FDA Rare Pediatric Disease Designation for Setrusumab for the Treatment of Osteogenesis Imperfecta
8:48am
6-K
EX-99.1
m2eni4jde5
25 Aug 20
Mereo BioPharma Announces Initiation of Placebo-Controlled Phase 1b/2 Clinical Trial with Alvelestat in COVID-19 Respiratory Disease
11:14am
6-K
ep524 n3y
3 Aug 20
Current report (foreign)
9:15am
F-3
yv6d5u fktefm19sr
6 Jul 20
Shelf registration (foreign)
4:58pm